# Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma

> **NCT00356460** · PHASE1 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 29 (actual)

## Conditions studied

- Carcinoma, Renal Cell
- Melanoma

## Interventions

- **BIOLOGICAL:** GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
- **BIOLOGICAL:** GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
- **BIOLOGICAL:** GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
- **BIOLOGICAL:** GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
- **BIOLOGICAL:** GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
- **BIOLOGICAL:** GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
- **BIOLOGICAL:** GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody
- **BIOLOGICAL:** GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody

## Key facts

- **NCT ID:** NCT00356460
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2014-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00356460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00356460, "Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00356460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*